Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.
Jesper van Breeschoten
,
Michel W J M Wouters
,
Doranne L Hilarius
,
John B Haanen
,
Christian U Blank
,
Maureen J B Aarts
,
Franchette W P J van den Berkmortel
,
Jan-Willem B de Groot
,
Geke A P Hospers
,
Ellen Kapiteijn
,
Djura Piersma
,
Roos S van Rijn
,
Karijn P M Suijkerbuijk
,
Willeke A M Blokx
,
Bert-Jan J Ten Tije
,
Astrid A M van der Veldt
,
Art Vreugdenhil
,
Marye J Boers-Sonderen
,
Alfonsus J M van den Eertwegh
More about this publication
British journal of cancer
Volume
126
Issue nr.
9
Pages
1362
Publication date
01-05-2022
Full text links
Publisher website (DOI)
10.1038/s41416-022-01772-z
Europe PubMed Central
35256756
Pubmed
35256756